PCSK9-LDLR相互作用的Allosteric抑制:用于小分子设计的结构见解
Yong Su Baek1, Siwoo Kim1, Eunho Lee1
1Atomatrix, 851, Daewangpangyo-ro 815, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea. sblee@atomatrix.co.kr.
Physical chemistry chemical physics : PCCP
|November 6, 2025
概括
使用分子动力学研究的小分子抑制剂向蛋白转化酶亚素/素9型 (PCSK9). 强效化合物保持抑制剂位点和LDL受体结合区域之间的通信,指导未来的药物设计.
科学领域:
- 生物化学和分子药理学
- 计算机化药物发现技术
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 是降低LDL胆固醇的验证目标.
- 针对PCSK9的单克隆抗体是有效的,但口服可用的小分子抑制剂受到蛋白质-蛋白质相互作用表面的限制.
研究的目的:
- 为了阐明以四化基因胺为基础的化合物抑制全性PCSK9的机制.
- 确定关键的相互作用和动态途径,对于强大的抑制至关重要.
主要方法:
- 用分子动力学 (MD) 模拟来分析结合模式和动力学.
- 相互信息 (MI) 分析被用来绘制PCSK9.9内的通信路径.
- 对同源抑制剂系列进行了能量和距离分析.
主要成果:
- 高亲和度抑制剂会激活关键残留物 (R357,R458,R476),形成一个稳定的静电网络.
- 强效的抑制剂在全位和LDLR结合段 (D374-C378) 之间保持长距离的通信.
- 弱抑制剂无法保护这种通信通路,类似于无抑制剂状态.
结论:
- 定义了一个结构动态轴,将局部结合连接到远程全沟通.
- 这些发现为设计下一代口服可用的PCSK9抑制剂提供了机制框架.
更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
14.0K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.8K
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
Allosteric Proteins-ATCase
6.4K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.4K
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Allosteric Regulation
62.9K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
62.9K
Protein-protein Interfaces
14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K
